

PA Health & Wellness Pharmacy and Therapeutics Committee Meeting Minutes
300 Corporate Center Drive, Suite 600, Camp Hill, PA 17011

Wednesday, April 13, 2022 – 12:00 PM – 1:30 PM

- Present:** Meghan McNelly, PharmD, Germaine Biksey, Jill Schaeffer, RN,
Dr. Mahmood Usman, Debbie Rose (Participant Advisory), Michelle Bennett, RPh, Dr. Keith Brown, Dr. Christopher Hughes,
Dr. Carla Huitt
- Absent:** Dr. Kolin Good, Dr. Venkateswara Davuluri
- Guests:** Amy Nowacki (Pharmacy), Jason Skaria (Pharmacy Manager), Shalyn Kline (Pharmacy), Marci Kramer (QI Director),
Evan Sebastian (Pharmacy), Tanayja Sams (Pharmacy), Jacci Rowe (Director, Compliance).
- Call to Order:** The PA Health & Wellness Pharmacy and Therapeutics Committee meeting called to order at 12:04 PM.
- Adjourned:** The PA Health & Wellness Pharmacy and Therapeutics Committee meeting was adjourned at 12:24 PM.
- Next Meeting:** Wednesday, July 13, 2022 – 12:00 PM
- Submitted By:** Shalyn Kline (PHW Pharmacy)

Committee Chair: _____
Shalyn Kline, PharmD

Date: 7/13/2022

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

Agenda Item	Discussion/Recommendation	Action	Next Steps	Owner
I. Introduction & Call to Order	Meghan McNelly called the PA Health & Wellness Pharmacy & Therapeutics Committee meeting to order at 12:04 PM.	Meeting Called to Order		Meghan McNelly
A. Introductions	None			Meghan McNelly
B. Announcements	<p>Meghan reminded all that 75% attendance is required for all voting members to remain as active committee members.</p> <p>Every month, a report is sent to the state. The state provides feedback, and the necessary follow-up is completed.</p>	No action required or taken.		Meghan McNelly
C. Explanation of the Review and Approval Process	<ul style="list-style-type: none"> i. Voting and vote totals ii. Tie breaker iii. Pennsylvania’s Review and Approval Process 	No action required or taken.		Meghan McNelly
D. Charter Review	The committee charter was reviewed with the committee members.	No action required or taken.		Meghan McNelly
II. Approval of Meeting Minutes	A vote was taken for the approval of the minutes from Q1_2022. No objections were made.	Adoption of Q1_2022 Meeting Minutes recorded as approved		Shalyn Kline
III. Old Business				
A. Policy Submission Status	There are no outstanding clinical policies awaiting approval.	No action required or taken.		Shalyn Kline

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).

B. COVID 19 Response	Continuing point-of-sale edits for “refill too soon”. State of emergency has not yet been lifted by the state, members will have 60 day notification of changes made.	No action required or taken.		Meghan McNelly
New Business				
A. Statewide PDL updates	According to the CHC contract, a compliance rate of 95 percent is expected. The compliance rate is currently being audited internally. The Pennsylvania Department of Human Services is conducting an audit of prior authorization determination data.			Shalyn Kline
B. Asthma	A vote was taken for the approval of the Asthma provider education. No objections were made.	The provider education was Committee approved.		Shalyn Kline
C. FDA Updates	This is informational only and addresses recalls, new drugs, etc. No vote necessary.	Informational		Shalyn Kline
D. Drug Coverage Criteria	Shalyn asked the Committee if anyone had issues with any of the supplemental drug list changes. There were no issues addressed. The Committee was asked if they had any issues with the Ambetter policy changes. There were no issues addressed.	The policy revisions were Committee approved.		Shalyn Kline
E. Complaints and Grievances Review	Shalyn stated that there were eight determinations upheld and six overturned. Seven of the fourteen determinations were for opioids. There are 5 others not counted that are still in the pre-grievance and will be reported on next P&T. Meghan stated that Shalyn Kline has designed fax forms to send to the providers that address specific criteria to help the provider be clearer in their response for a prior authorization. She also stated that electronic prior authorization submissions are not receiving enough information for approvals and will be a point of focus going forward.			Shalyn Kline/Meghan McNelly

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).

<p>F. Drug Utilization Review</p>	<p>Shalyn presented the drug utilization review, noted the numbers are only for the first 2 months of the quarter. Last month will be reported during the next P&T.</p> <p>FWA – There were 34 Participants reviewed with 90 Morphine Milligram Equivalent (MME) or more. No issues were found. No Participants were identified with three or more practices/hospitals prescribing opioids.</p> <p>Inappropriate prescribing – No Participants were identified potentially using >4gm/day.</p> <p>Disease management – There were 18 identified long-acting beta-agonist monotherapy. All were reviewed.</p>			<p>Shalyn Kline</p>
<p>G. PBM Oversight</p>	<p>In Q1, there were 100 requests audited. (20 approvals, 80 denials).</p> <p>Findings for the denials were 21 requests had errors in the denial language and six requests the wrong policy was utilized. Five denials were issued by RPh instead of medical director. Two turn around times were missed due to outside vendor medical director reviews.</p> <p>Coaching was completed with the Envolve clinical reviewers to prevent future occurrences.</p> <p>Meghan stated at the end of March the state placed PHW and Envolve under a remediation plan for prior authorization. There are now multiple levels of reviews to ensure accuracy of both approvals and denials.</p>			<p>Jason Skaria/ Meghan McNelly</p>
<p>K. Open Forum</p>	<p>Debbie brought up a concern about participants receiving letters in their preferred language. Meghan stated there are multiple languages listed in the denial paperwork that explain how to receive documentation in another preferred language.</p>	<p>PHW will determine if participant language for</p>		<p>Meghan McNelly</p>

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).

		prior authorization letters can be chosen		
Adjournment	The meeting was adjourned at 12:24 pm	Meeting adjourned		Meghan McNelly

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).